Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, Yoshino T, Saji S, Matsuda F. Kanai M, et al. Among authors: matsui t. Cancer Med. 2023 Apr;12(7):7808-7814. doi: 10.1002/cam4.5541. Epub 2022 Dec 16. Cancer Med. 2023. PMID: 36524458 Free PMC article.
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Kotaka M, et al. Among authors: matsui t. Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16. Cancer Chemother Pharmacol. 2015. PMID: 25983021 Free PMC article. Clinical Trial.
JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer.
Yoshino T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Munemoto Y, Takagane A, Ishikawa H, Ishida H, Ogata Y, Oba K, Goto K, Sakamoto J, Maehara Y, Ohtsu A. Yoshino T, et al. Among authors: matsui t. Cancer Chemother Pharmacol. 2019 Dec;84(6):1269-1277. doi: 10.1007/s00280-019-03957-5. Epub 2019 Sep 23. Cancer Chemother Pharmacol. 2019. PMID: 31549217 Free PMC article. Clinical Trial.
[Various pitfalls in cancer clinical trials].
Sakamoto J, Matsui T, Kodera Y. Sakamoto J, et al. Among authors: matsui t. Gan To Kagaku Ryoho. 2009 Feb;36(2):161-70. Gan To Kagaku Ryoho. 2009. PMID: 19223730 Review. Japanese.
Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer.
Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, Hayashi T, Cho H, Tsuburaya A, Miyashita Y, Sakamoto J. Yoshikawa T, et al. Among authors: matsui t. Eur J Cancer. 2016 Jul;62:103-11. doi: 10.1016/j.ejca.2016.04.012. Epub 2016 May 28. Eur J Cancer. 2016. PMID: 27244537 Free article. Clinical Trial.
4,232 results